UNSPSC 51171931: Cetraxate

This classification denotes an anxiolytic with the molecular formula C17H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VPA8CPF0N, chemically known as hydrocinnamic acid, p-hydroxy-, 4-(aminomethyl)cyclohexanecarboxylate, trans- but generally known as cetraxate, which bears US NIH Compound Identifier 2680. European Medicines Agency schedules Cetraxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07457MIG.

UNSPSC 51171931 Cetraxate, a Commodity code, reflects state and local government procurement of pharmaceutical products for clinical testing, criminal justice supervision, and public health programs. The recent solicitations show state and local buyers acquiring cetraxate and related drugs through cooperative purchasing agreements, direct-to-manufacturer pharmacy initiatives, and specialized testing-service contracts. Collin County Community Supervision and Corrections Department, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), and the Texas Health and Human Services Commission are the issuing bodies represented in recent activity. The work spans immunoassay screening supplies for drug-testing programs, generic pharmaceuticals for multi-state cooperative purchasing, and pharmacy benefit program inputs—a diverse portfolio that reflects how state agencies, county corrections departments, and cooperative purchasing vehicles source both branded and generic pharmaceutical inventory to support testing, treatment, and custody operations.

Recent opportunities include Collin County's RFP 2026-327 (posted July 9, 2026, due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years plus optional renewals, requiring vendors to supply immunoassay screening and confirmation testing for approximately 25,031 annual tests; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities with contracts effective July 1, 2026; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities for a Therapeutic Pharmacy Initiative. Activity concentrates in Texas and Minnesota, with MMCAP's cooperative model extending to Oregon and other participating jurisdictions. Collin County's two-year contract term with potential three one-year renewals and MMCAP's alignment through June 30, 2028 signal sustained demand for pharmaceutical inventory and testing-related products under this code.